FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 翰思艾泰生物醫藥科技（武漢）股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2026年3月31日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 03378 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事 ...

（於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 翰思艾泰生物醫藥科技（武漢）股份有限公司 除上述對組織章程細則的修訂外，組織章程細則的其他條款維持不變。上述組織章 程細則修訂的英文版本為其中文版本的非官方翻譯。如有任何差異，概以中文版本 為準。 建議修訂組織章程細則須待本公司股東於應屆2025年股東週年大會（「股東週年大 會」）上通過特別決議案批准後，方可作實，並將自股東週年大會上相關決議案獲批 准之日起生效。載有上述建議修訂組織章程細則詳情及股東週年大會通告的通函將 於適當時候寄發予要求索取印刷本的本公司股東。 （股份代號：3378） 建議修訂組織章程細則 本公告由翰思艾泰生物醫藥科技（武漢）股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則（「上市規則」）第13.51(1)條作出。 考慮到本公司的實際情況 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 翰思艾泰生物醫藥科技（武漢）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3378） 持續關連交易 修訂年度上限 修訂年度上限 茲提述招股章程中「關連交易」一節，內容有關（其中包括）本集團與中美華世通生 物醫藥科技之間的持續關連交易。 本公司與中美華世通生物醫藥科技於2025年12月10日訂立原材料供應框架協議， 據此，華世通集團將向本集團供應小分子，用作開發ADC產品。董事會已審閱及 評估現有原材料供應框架協議項下的持續關連交易，並預期本集團對小分子的需 求將超過其過往項目，以致原材料供應框架協議項下交易的現有年度上限將不足 以滿足本集團的需求。因此，本公司擬將截至2026年12月31日止年度及截至2027 年12月31日止年度的年度上限分別增加至人民幣6.5百萬元及人民幣5.0百萬元。 上市規 ...

Financial Performance - Total revenue for 2025 reached RMB 16.616 million, a significant increase of 116% compared to RMB 7.681 million in 2024[4] - The company reported a net loss of RMB 131.494 million for 2025, compared to a loss of RMB 116.922 million in 2024, indicating a 12.4% increase in losses[4] - The company's other income and gains increased by 115.6% from approximately RMB 7.7 million in 2024 to about RMB 16.6 million in 2025, primarily due to changes in the fair value of contingent consideration[32] - The annual loss increased from approximately RMB 116.9 million in 2024 to about RMB 131.5 million in 2025[37] - The company reported a pre-tax loss of RMB 145,036,000 for 2025, compared to a loss of RMB 122,820,000 in 2024, indicating a deterioration of 18.1%[40] - The basic and diluted loss per share for the year was RMB 1.11, compared to RMB 0.98 in 2024, indicating a worsening of 13.3%[40] Research and Development - Research and development expenses for 2025 were RMB 89.363 million, up 19.6% from RMB 74.721 million in 2024[4] - The company has established a product pipeline with 3 candidates in clinical stages and 1 in IND approval stage, focusing on oncology and autoimmune diseases[6] - The flagship product HX009 achieved preliminary efficacy data in clinical trials for EBV+ non-Hodgkin lymphoma and melanoma, validating its dual-target mechanism[7] - The first FIC ADC product HX111 received NMPA IND approval, marking a key milestone in the company's ADC strategy[7] - The VersatiBody™ platform successfully advanced two clinical-stage dual-function antibodies, demonstrating high design efficiency and drugability optimization[7] - HX301, a novel oral multi-kinase inhibitor, is in Phase IIa trials targeting four oncogenic pathways, focusing on difficult-to-treat solid tumors like glioblastoma[15] - The autoRx40™ platform is advancing the development of several candidates targeting autoimmune diseases, enhancing the company's capabilities in antibody drug development[23] - The platform strategy allows for efficient iteration and output of candidate drugs, significantly reducing R&D costs and enhancing efficiency, positioning the company for long-term growth[24] Clinical Trials and Product Development - The company initiated a clinical study for HX009 in combination with INX1008 for advanced cholangiocarcinoma, with 9 patients enrolled in 2025[12] - The company aims to prioritize the clinical development of HX009 for EBV+ non-Hodgkin lymphoma, with further evaluation for other indications pending data maturity[10] - The company has expanded its global clinical layout, with simultaneous patient enrollment in China and Australia for HX044[7] - The company is advancing its single-agent treatment with clinical trials in Australia and China, aiming to enroll 8 late-stage solid tumor patients in Australia by 2025 and 18 patients in China by January 2025[13] - HX044 targets ICI-resistant tumors with a dual-target mechanism, establishing a competitive edge in the tumor immunotherapy sector, and will accelerate data collection on safety and efficacy while progressing combination therapy trials[14] - By September 2025, the company plans to initiate clinical studies for HX044 in combination with PD-1 monoclonal antibody, enrolling 2 patients within the year to provide a new treatment option for resistant solid tumors[16] - The Phase I trial for HX301 is expected to demonstrate disease stability in late-stage solid tumor patients at doses of 80mg and above, providing a solid basis for future combination therapies[17] - HX111, the company's first ADC candidate, is set to submit its IND application by the end of 2025, marking a significant milestone in the ADC field, with plans to start Phase I trials in early 2026[19] - The VersatiBody™ platform has successfully produced two FIC clinical-stage dual-function fusion proteins and several ADC candidates, showcasing its efficiency in drug development[22] - The company has established a pipeline consisting of 3 clinical-stage products, 1 IND-approved product, and multiple preclinical candidates, covering tumor immunology, ADC cancer treatment, and autoimmune diseases[25] Financial Position and Cash Flow - As of December 31, 2025, the total cash and cash equivalents amounted to approximately RMB 614.4 million, a 281% increase from about RMB 161.2 million as of December 31, 2024[38] - The current assets were approximately RMB 691.8 million, while current liabilities were about RMB 95.1 million, which included interest-bearing bank loans of approximately RMB 30.0 million[38] - The debt-to-asset ratio decreased from approximately 56.8% as of December 31, 2024, to 20.0% as of December 31, 2025[39] - Total current assets rose to RMB 691,825,000 in 2025, compared to RMB 242,787,000 in 2024, representing an increase of 185.5%[41] - Total liabilities decreased from RMB 197,440,000 in 2024 to RMB 95,114,000 in 2025, a reduction of 51.8%[41] - The company's total assets decreased to RMB 1,034,476,000 in 2025 from RMB 1,001,000,000 in 2024, a decline of 3.2%[41] - The company’s equity increased significantly to RMB 747,619,000 in 2025 from RMB 216,604,000 in 2024, reflecting a growth of 245.5%[42] Administrative and Other Expenses - Administrative expenses increased by 25.2% from approximately RMB 35.5 million in 2024 to about RMB 44.4 million in 2025, mainly due to higher professional service costs and personnel expenses[34] - The company's listing expenses rose by 27.4% from approximately RMB 10.7 million in 2024 to about RMB 13.7 million in 2025, attributed to costs associated with the successful IPO on December 23, 2025[35] - Financial costs increased by 23.4% from approximately RMB 9.4 million in 2024 to about RMB 11.6 million in 2025, mainly due to increased interest on redeemed debt and bank loans[36] Corporate Governance and Shareholder Information - The board of directors does not recommend the payment of a final dividend for the year ending December 31, 2025[79] - The company has adopted corporate governance practices based on the principles and code provisions of the corporate governance code since the listing date[68] - The audit committee, consisting of three independent non-executive directors, has reviewed the consolidated annual results for the year ending December 31, 2025[76] - The company has not engaged in any major litigation or arbitration during the reporting period[72] - The board expresses gratitude to shareholders, customers, and suppliers for their continuous support[83] - The management team and employees are acknowledged for their outstanding achievements and dedication to improving company management[83] - The board includes both executive and non-executive directors, highlighting a diverse leadership structure[85] IPO and Future Plans - The net proceeds from the initial public offering (IPO) on December 23, 2025, amounted to approximately HKD 531.3 million, which remains unutilized[74] - The company plans to allocate 35% of the IPO proceeds (approximately HKD 185.96 million) for the research and development of its core product HX009[74] - 33% of the IPO proceeds (approximately HKD 175.33 million) will be used for the research and development of major products HX301 and HX044[74] - The company has not utilized any of the IPO proceeds since the listing date and plans to use them according to the stated purposes in the prospectus by 2030[75] - There are no significant events following the reporting period up to the date of this announcement[78]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 翰思艾泰生物醫藥科技（武漢）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 董事會會議通告 翰思艾泰生物醫藥科技（武漢）股份有限公司（「本公司」）董事（「董事」）會（「董事會」） 謹此宣佈，董事會會議將於2026年3月27日（星期五）舉行，藉以考慮及批准本公司 及其附屬公司截至2025年12月31日止的年度業績及其發布，並考慮建議派發末期股 息（如有）。 承董事會命 翰思艾泰生物醫藥科技（武漢）股份有限公司 董事長兼執行董事 張發明博士 香港，2026年3月17日 於本公告日期，董事會包括：(i)執行董事張發明博士、李其翔博士、劉敏先生及肖 婕妤女士；(ii)非執行董事李健博士；及(iii)獨立非執行董事畢紅鋼博士、陳奇峰先 生、王世雄先生及張瓊光博士。 （股份代號：3378） ...

呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03378 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 136,218,830 | RMB | | 0.1 RMB | | 13,621,883 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 136,218,830 | RMB | | 0.1 RMB | | 13,621,883 | FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 翰思艾泰生物醫藥科技（武漢）股份有限公司（於中華人民共和國註冊成立的 ...

Group 1 - The company Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced the resignation of Mr. Zhang Hui from his positions as Co-Company Secretary, Deputy General Manager, Chief Financial Officer, and Board Secretary due to personal career planning reasons, effective from February 8, 2026 [2][14][24] - Ms. Xiao Jieyu has been appointed as the new Chief Financial Officer and Board Secretary, effective from February 8, 2026, with an annual base salary of RMB 750,000 and discretionary bonuses based on her performance and the overall performance of the group [2][12][24] Group 2 - Ms. Xiao Jieyu, aged 43, holds a Bachelor's degree in Plant Protection from Huazhong Agricultural University and a Master's degree in Pharmacology from Shanghai Pharmaceutical Industry Research Institute [3][15] - Prior to joining the company, Ms. Xiao held various positions in investment and financing roles, including Senior Investment Manager at Wuhan Optics Valley Venture Capital and Deputy General Manager at Wuhan East Lake High-tech Equity Investment Management Co., Ltd. [4][16] Group 3 - Mr. Zhang Hui, aged 56, joined the company in August 2024 and was responsible for overseeing the financial operations, corporate governance, investor relations management, and company secretarial matters [5][17] - Mr. Zhang has over 16 years of experience in investment banking and financing, having worked at various institutions including DBS Bank, BNP Paribas, and Deutsche Bank [6][18]

Group 1 - The company plans to acquire 70% equity of Xiamen Container Terminal Group from Xiamen International Port by issuing shares and cash payments [1] - The company aims to raise supporting funds not exceeding 3.5 billion yuan from no more than 35 specific investors [1] - On February 13, 2026, the company received approval from the China Securities Regulatory Commission to issue 796,854,165 shares for the asset purchase and to raise supporting funds [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 特別決議案 | 票數(%) | | | | --- | --- | --- | --- | | | 贊成 | 反對 | 棄權 | | 審議及批准於有關期間授予董事會一 | 98,771,940 | 400 | 0 | | 般授權以購回H股 | (99.9996%) | (0.0004%) | (0.0000%) | Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 翰思艾泰生物醫藥科技（武漢）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3378） 公告 於2026年2月12日舉行的臨時股東大會投票表決結果 茲提述翰思艾泰生物醫藥科技（武漢）股份有限公司（「本公司」））日期為2026年1月27 日的通函（「通函」）。除非文義另有所指，本文中所使用的詞彙與通函所定義者具有 相同涵義。 本公司於2026年2月12日（星期四）上午十時正假座中國湖北 ...

執行董事 張發明博士 （董事會主席） 李其翔博士 劉敏先生 肖婕妤女士 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 翰思艾泰生物醫藥科技（武漢）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3378） 董事名單與其角色及職能 翰思艾泰生物醫藥科技（武漢）股份有限公司（「本公司」）董事會（「董事會」）成員（「董 事」）載列如下： 畢紅鋼博士 陳奇峰先生 王世雄先生 張瓊光博士 董事會設有三個董事委員會。下表提供該等董事委員會的成員資料。 非執行董事 李健博士 獨立非執行董事 | | 董事委員會 | | | | | --- | --- | --- | --- | --- | | 董事 | | 審核委員會 | 提名委員會 | 薪酬委員會 | | 張發明博士 | | | C | | | 李其翔博士 | | | | M | | 劉敏先生 | | | | | | 肖婕妤女士 | | | M | | | 李健博士 | | | | | | 畢紅鋼博士 | | | M | M | | 陳奇峰先生 | | C | M | | | 王世雄先生 | | M | | C ...